Latest Research Reports

Diagnosed incident cases of cystic fibrosis are set to decrease

Diagnosed incident cases of cystic fibrosis are set to decrease

Novartis, Pfizer, Amgen, and Merck: key players in the autoimmune biosimilars space

Novartis, Pfizer, Amgen, and Merck: key players in the autoimmune biosimilars space

EMA set to approve plethora of oncology drugs

EMA set to approve plethora of oncology drugs

The global burden of rheumatoid arthritis will increase

The global burden of rheumatoid arthritis will increase

US and UK stand out with higher disease prevalence of two autoimmune diseases

US and UK stand out with higher disease prevalence of two autoimmune diseases

The launch of long-acting therapies will drive the growth of the growth hormone deficiency Market

The launch of long-acting therapies will drive the growth of the growth hormone deficiency Market

Is diagnosed non-invasive ductal carcinoma in-situ breast cancer rarer in China?

Is diagnosed non-invasive ductal carcinoma in-situ breast cancer rarer in China?

Anticipated approval timeline of PARP inhibitors in HER2-negative breast cancer

Anticipated approval timeline of PARP inhibitors in HER2-negative breast cancer

A look at atrial fibrillation’s market size forecast

A look at atrial fibrillation’s market size forecast

Will competitive US pricing be enough to give Valeant’s Siliq an edge?

Will competitive US pricing be enough to give Valeant’s Siliq an edge?

Eylea enables Regeneron to dominate the ocular market

Eylea enables Regeneron to dominate the ocular market

Dark clouds: the growing burden of major depressive disorder

Dark clouds: the growing burden of major depressive disorder

Seven kings of diabetes will remain in power for years to come

Seven kings of diabetes will remain in power for years to come

Biogen will retain the lion’s share of the neurology market

Biogen will retain the lion’s share of the neurology market

Surge in deals promises a brighter future for fatty liver disease

Deals involving drugs to treat fatty liver disease (FLD) hit an all-time high in 2016, with more than twice as many completed as in any year...

Surge in deals promises a brighter future for fatty liver disease

Non-alcoholic steatohepatitis cases expected to nearly double over next decade

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of fat in the liver, in addition to liver inflammation and...

Non-alcoholic steatohepatitis cases expected to nearly double over next decade

NSCLC incidence continues to increase in urban China

Lung cancer has become the most common cancer in China. GlobalData’s epidemiology forecast for non-small cell lung cancer (NSCLC),...

NSCLC incidence continues to increase in urban China

Asia's growing burden of an ageing population and colorectal cancer

Recent cancer surveillance data shows that in the past decade, Asian countries such as China and Japan have experienced an increase in new cases of colorectal cancer (CRC)....

Asia's growing burden of an ageing population and colorectal cancer

Biosimilars put top selling cancer drug under threat

The recent European Medicines Agency (EMA) approval of the first rituximab biosimilar has placed a top selling cancer drug, Roche’s Rituxan/Mabthera (rituximab), under...

Biosimilars put top selling cancer drug under threat

VTE: too many at-risk patients are not being treated

Venous thromboembolism (VTE), which comprises of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that blocks blood flow. VTE...

VTE: too many at-risk patients are not being treated

Drivers for the next decade of diabetic foot ulcer drug sales

The ever-increasing prevalence of diabetes, along with the anticipated launch of a novel wound healing agent, will lead to significant growth of the US Diabetic Foot Ulcer (DFU) market through...

Drivers for the next decade of diabetic foot ulcer drug sales